New biomarkers for Alzheimer's disease, depression and beyond

New biomarkers are being developed to improve the diagnosis and treatment of neurological and psychiatric conditions like Alzheimer's and depression. These tools aim to provide objective measures for conditions that have historically been difficult to track.
Why it matters
Advancements in biomarkers could significantly improve patient outcomes by enabling earlier intervention and more personalized treatment plans.
edited by Sadie Harley , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: Pixabay/CC0 Public Domain Newly developed biomarkers may enhance clinicians' ability to detect and treat disorders of the nervous system, including Alzheimer's disease, mood disorders and neurodevelopmental conditions. The findings were presented at Neuroscience 2026 , the annual meeting of the Society for Neuroscience.
Neurological and psychiatric conditions affect billions of people worldwide and are a leading cause of disability. Biological markers, or biomarkers, could help doctors better diagnose and treat these diseases. The use of biomarkers is now commonplace in fields such as cancer biology, cardiovascular disease and genetic disorders.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in